Lmr Partners LLP Intellia Therapeutics, Inc. Transaction History

Lmr Partners LLP

$10.9 Billion
Q3 2024

A detailed history of Lmr Partners LLP transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Lmr Partners LLP holds 71,100 shares of NTLA stock, worth $868,842. This represents 0.01% of its overall portfolio holdings.

Number of Shares

71,100

Previous 52,567 35.26%

Holding current value

$868,842

Previous $1.18 Million 24.23%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$19.72 - $27.36 $365,470 - $507,062	18,533 Added 35.26%	71,100 $1.46 Million
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $452,632 - $615,416	22,609 Added 75.47%	52,567 $1.18 Million
Q1 2024 May 15, 2024	BUY	$23.82 - $32.8 $58,787 - $80,950	2,468 Added 8.98%	29,958 $824,000
Q4 2023 Feb 14, 2024	SELL	$23.16 - $32.34 $64,848 - $90,552	-2,800 Reduced 9.24%	27,490 $838,000
Q3 2023 Nov 14, 2023	BUY	$31.62 - $45.78 $366,792 - $531,048	11,600 Added 62.07%	30,290 $957,000
Q2 2023 Aug 14, 2023	BUY	$34.58 - $46.03 $646,300 - $860,300	18,690 New	18,690 $762,000
Q4 2022 Feb 14, 2023	SELL	$33.21 - $62.69 $359,199 - $678,055	-10,816 Reduced 45.05%	13,192 $460,000
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $531,435 - $706,675	9,856 Added 69.64%	24,008 $1.34 Million
Q2 2022 Aug 15, 2022	SELL	$38.49 - $76.21 $134,599 - $266,506	-3,497 Reduced 19.81%	14,152 $733,000
Q1 2022 May 16, 2022	BUY	$58.27 - $118.99 $1.03 Million - $2.1 Million	17,649 New	17,649 $1.28 Million

Others Institutions Holding NTLA

# of Institutions

313

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $929M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.

Account